News2020-05-23T14:50:18+00:00

Read Our Recent News

NanoMab To Initiate FIH for 99mTc-NM-02 at SGH

Date: Aug 1st, 2019 NanoMab To Initiate FIH for 99mTc-NM-02 at SGH Shanghai, China, August 1st, 2019. NanoMab announced that it has decided to initiate FIH with 99mTc-NM-02, which is the company’s breast cancer program. The kick off meeting was held at Shanghai General Hospital (SGH). The primary objective of this study is to evaluate safety, tolerability and pharmacokinetics of 99mTc-NM-02. 99mTc-NM-02 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of HER2 expression in patients [...]

August 1st, 2019|

NanoMab Presents at SNMMI

Date: June 24th, 2019 NanoMab Presents at SNMMI Anaheim, California, US, June 24th, 2019. Gitasha Chand, clinical research director of NanoMab presented NanoMab’s FIH data of 99mTc-NM-01 at the annual meeting of Society of Nuclear Medicine and Molecular Imaging (SNMMI). 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment Also see link: Early phase I study of a 99m Tc labeled anti-PD-L1 sdAb in SPECT/CT [...]

June 24th, 2019|

NanoMab and Lantheus enter into License Agreement Regarding the Commercial Development of 99mTc-NM-01

Date: May 29th, 2019 NanoMab and Lantheus enter into License Agreement Regarding the Commercial Development of 99mTc-NM-01 Shanghai, China, May 29th, 2019. NanoMab announced a collaboration with Lantheus Medical Imaging, Inc. (LMI) to provide 99mTc-NM-01 as clinical research tool, together with support and analytics, to pharmaceutical companies and the largest academic centers conducting clinical research in immuno-oncology in North America and Europe. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in [...]

May 29th, 2019|

Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society

Date: April 1st-3rd, 2019 Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society London, UK, April 1st-3rd, 2019. Gary Cook, scientific advisor of NanoMab presented 99mTc-NM-01 clinical data at the annual meeting of British Nuclear Medicine Society (BNMS) and was awarded with 2nd Oral Prize for his presentation ‘Imaging Programmed Cell Death Ligand-1 (PDL1) Expression in Non-Small Cell Lung Cancer with 99mTc anti PDL1 sdAb SPECT’.   99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and [...]

April 1st, 2019|

NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine

Date: Feb 22nd, 2019 NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine Shanghai, China, February 22nd, 2019. NanoMab published its FIH data for the first 16 patients of 99mTc-NM-01 on Journal of Nuclear Medicine (JNM), titled ‘Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer’. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression [...]

February 22nd, 2019|

NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study

Date: Feb 7th, 2019 NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study London, UK, February 7th, 2019. NanoMab announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust on the investigator-initiated study for 99mTc-NM-01. The primary objective is to assess the change in PD-L1 expression in relation to immunotherapy in NSCLC and melanoma patients. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression [...]

February 7th, 2019|

Contact Us With Any Questions

Please do not hesitate to get in touch with any questions.

CONTACT US